MDS Analytical Technologies Launches Molecular Devices® SpectraTest® LM1 Luminescence Validation Package to Meet User Needs
Product News Jan 25, 2010
MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life-sciences research, today announced the launch of the Molecular Devices® SpectraTest® LM1 Luminescence Validation Package.
The new LM1 Validation Package, which is commercially available, is the latest addition to an ever-growing validation and compliance product line, and is a direct response to customers’ needs. With both single- and multi-mode luminescence microplate readers becoming more popular among research scientists, users of these systems have a real need to be able to validate instrument performance. The new LM1 Validation Package provides users with such a tool, giving them the ability to test optical specifications of MDS Analytical Technologies’ microplate readers.
“All SpectraTest® Validation and Compliance Tools provide users an automated, traceable method for instrument validation that delivers less variability than traditional techniques and interrogates 13 critical parameters of instrument performance,” said Andy Boorn, President of MDS Analytical Technologies. “This gives our users an extremely high degree of confidence in the performance of their instrument systems, which translates into the same level of confidence in the quality of their research results.”
Validation and compliance tools are essential for users in laboratories that must adhere to quality and regulatory requirements. To meet the validation and compliance needs of all of its users, MDS Analytical Technologies provides additional tools for IQ/OQ/PQ validation as well as software validation, and offers compliance tools to help users meet quality and regulatory requirements, such as United States Food and Drug Administration (FDA) 21CFR Part 11 compliance and Good Laboratory and Manufacturing Practices (GxP). These tools facilitate users’ performance certification and qualification.